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clinical diagnosis (degree I-III). 141 healthy subjects from Xi’an city were chosen and 
matched by age and sex. The study was performed in accordance with the Declaration 
of Helsinki and approved by the Human Ethics Committee of Xi’an Jiaotong University. 
Informed written consent was obtained from each subject. The staple food ( flour, 
rice and corn hazel) and hair from children and healthy subjects were collected. 
The selenium level in hair and staple food was tested with Atomic Fluorescence 
Spectrophotometer. Results: About 65 children which the total number of children 
was 1743 were KBD X-ray positive. The selenium level in hair of children from xunyi 
county was significantly lower than healthy subjects from Xi’an city (0.24 and 0.62 
μ g/g respectively, P< 0.05). No difference was found in selenium level of staple food 
between children from xunyi county and the control group (P> 0.05). ConClusions: 
The abnormal ration of X-ray in children from xunyi county was lower than 5%. 
Although prevention and control measures have been implemented, the selenium 
level in hair of children from xunyi county was still lower. Children lived in xunyi 
county should intake more Se to prevent KBD. This research is supported by National 
Natural Science Foundation (No. 81172610), Huimin projects of Ministry of Science and 
Technology (No. 2012GS610101), Science and technology projects of Shaanxi province 
health department (No. 2014ZD072) and projects of Shaanxi Province Administration 
of traditional Chinese Medicine (13-LC085).
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objeCtives: Excessive fluoride ingestion causes a disease known as fluoro-
sis which prevailing in more than 50 countries and regions. A large number of 
studies have shown that excess fluoride can cause human reproductive system 
damage. Therefore, we investigated the possible association between estrogen 
(E2) level with fluorosis and the role of selenium in fluorosis women in Shaanxi 
province. Methods: Ziyang County of Ankang City has higher environmental 
selenium level, while the Hanbin district of Ankang City has lower environmental 
selenium level. Ziyang County and Hanbin district of Ankang City were both the 
serious fluorosis areas. The fluorosis women patients from different environmental 
selenium level area and the healthy volunteer were divided into three groups: “High 
Se + F group” (n= 50), “High F group” (n= 50) and “Control group” (n= 46). All women 
were among 20 to 49 years old. E2 level was examined by ELISA kit. The selenium 
level in hair was tested with Atomic Fluorescence Spectrophotometer. Results: 
The E2 was significantly lower in “High F group” than that in “High Se + F group” 
and “Control group” (27.11±1.91, 60.22±6.95, 63.57±2.24 pg/ml, respectively). The 
mean for total Se concentration in hair was different: 3.67±0.16 μ g/g in “High Se 
+ F group”, 0.99±0.09 μ g/g in “High F group” and 0.66±0.13 μ g/g in “Control group”, 
respectively. ConClusions: The E2 level in fluorosis women was lower than that 
in control group women, while the Se has the protective effect against fluoride by 
increasing the E2 level. Women lived in fluorosis areas should intake more Se to 
prevent ovarian function damage induced by fluoride. This research was supported 
by National Natural Science Foundation (No. 81172610), Huimin projects of Ministry 
of Science and Technology (No. 2012GS610101), Science and technology projects 
of Shaanxi province health department (No. 2014ZD072) and projects of Shaanxi 
Province Administration of traditional Chinese Medicine (13-LC085).
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BuDgeT iMPacT analySiS oF ToFaciTiniB FoR RheuMaToiD aRThRiTiS 
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objeCtives: To assess the budget impact of tofacitinib standardization in Brazilian 
private healthcare system for the treatment of moderate to severe Rheumatoid 
Arthritis (RA). Methods: An analytical decision-making model was developed in 
order to simulate the costs of standardization of tofacitinib in the list of therapies 
available for the treatment of moderate to severe RA in the supplemental healthcare 
system (SS) in a time horizon of five years. The reference population was composed 
by applying the RA prevalence in the Brazilian population to the number of SS ben-
eficiaries for the year of 2015 which result n= 233,722 beneficiaries. For the analysis, 
the tofacitinibe cost of treatment was compared to the average cost of the therapy 
with a biological DMARD. For both, the following were also taken into consideration: 
(i) drug cost – an estimate through the technology list price; (ii) assumed projection 
for tofacitinib diffusion rate in the private healthcare system; (iii) micro-costing 
of disease follow-up costs; (iv) micro-costing of (subcutaneous and intravenous) 
administration costs; (v) market share of biological therapies in the Brazilian market, 
for which projection was obtained from IMS Health data (2014). All monetary units 
were in BRL. Results: The total cost of tofacitinib treatment is lower than the 
mean total cost of treatment with biological DMARDs, with an approximate reduc-
tion of 25.22%. Considering the assessed time horizon and the estimated diffusion 
rate for tofacitinib in relation to the biological therapy for SS beneficiaries in 2015, 
tofacitinib may yield savings of approximately 2% in 2015, 3% in 2016, 4% in 2017, 
5% in 2018, 6% in 2019, adding up an accrued of approximately 20% in the first five 
years of its standardization in the SS. ConClusions: The use of tofacitinib may 
decrease the total treatment costs in the Brazilian private healthcare system for 
patients with moderate to severe RA.
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Significant correlations were revealed between the occurrence of osteonecrosis 
and age (year, HR= 0.974), female gender (female/male, HR= 2.978), fracture displace-
ment (displaced/non-displaced, HR= 1.998) and the season of surgery (fall/winter, 
HR= 0.372; spring/winter, HR= 0.602, summer/winter, HR= 0.455). ConClusions: 
Wintertime osteosynthesis increases the risk of osteonecrosis. The findings raise 
the possibility of association between seasonal changes in vitamin D levels and 
impaired fracture healing of femoral neck fracture. The results may help establish 
an effective strategy for the prevention of serious complications.
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objeCtives: Hip fractures are followed by increased mortality in the elderly. The 
study was carried out to analyse the mortality rate and predictors for mortality 
over 10 year period in patients over 60 years suffered from primary femoral neck 
fractures. Methods: Data from patients aged 60 years and over undergoing pri-
mary surgical treatment after femoral neck fractures in the year 2000 were collected 
from database of Hungarian National Health Insurance Fund. The mortality was 
analysed for the period 2000-2010. The following risk factors were investigated: age, 
gender, type of fracture, comorbidities, type of surgery, time to surgery and further 
surgical treatment. Predictors for mortality were evaluated by Cox proportional 
hazard model and logistic regression analysis using yearly intervals. The patients’ 
survival was investigated by Kaplan-Meier analysis and log-rank test. Results: 
3783 patients were included the study. The mortality rate was 30.76% in the first 
year, and 80.65% at 10 years. The mortality showed a tendency to decrease during the 
follow-up period. Cox regression identified higher age (years, HR= 1.024), male gen-
der (female/male, HR= 0.776), fracture type (extracapsular/GardenI-II, HR= 1.276, and 
GardenIII-IV/GardenI-II, HR= 1.194), comorbidities (presence/absence, HR= 1.361), 
type of surgical methods (arthroplasty/osteosynthesis, HR= 0.750), surgery delay 
more than 12 hours (12-24/0-6 hours, HR= 1.188) and absence of further surgical 
treatment (presence/absence, HR= 0.756) as significant risk factors for overall mor-
tality. Logistic regression analysis showed significantly higher risk of men up to 5 
years, higher age up to 10 years, comorbidities up to 4 years, type of fracture and 
surgical delay of the primary treatment up to 2 years. Kaplan-Meier method gave 
parallel results with risk factor analysis. ConClusions: Assessing the impact of 
risk factors on 10 year mortality after primary femoral neck fracture is difficult. We 
found associations between clinical determinants and late mortality, which require 
further investigations regarding the long period of time until death.
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objeCtives: Glutathione peroxidase 1 (GPx1) is a ubiquitously expressed sele-
nium-dependent enzyme that protects cells against oxidative damage by reducing 
hydrogen peroxide and a wide range of organic peroxides. In the present study, we 
investigated the possible association between the proline-leucine polymorphism 
(198Pro/Leu, rs1050450) present in the GPx1 gene and the susceptibility of Kashin-
Beck disease (KBD) in a Chinese population. Meanwhile, we detected the mRNA 
expression of GPx1 in blood and cartilage tissues between KBD and controls in 
order to analyze the transcriptional activity of GPx1 and explore molecular mecha-
nism of KBD. Methods: The GPx1 Pro198Leu genotype was determined in 161 
KBD cases and 312 control individuals with polymerase chain reaction-restriction 
fragment length polymorphism assay (PCR-RFLP). The mRNA expression level of 
GPx1 was detected by Real-time PCR. Results: The genotypic and allelic frequency 
of GPX1 were different statistically between KBD patients and healthy controls 
(P= 0.016, 0.043, respectively). We found an overall protective effect of the Pro/Pro 
genotype on the risk of KBD. Carriers of Pro/Leu and Leu/Leu had an increased risk 
of KBD compared with homozygous wild-type (Pro/Pro) individuals (OR, 1.781; 95% 
CI, 1.127-2.814; P = 0.016). The results of Real-time PCR showed a significant dif-
ference of mRNA level of GPx1 in whole blood between the two groups (P= 0.026), 
and expression of GPx1 mRNA in KBD patients decreased significantly coampared 
with controls. However, no significant difference was observed in cartilage tissues 
(P= 0.162). ConClusions: The study suggested that the 198Pro/Leu polymorphism 
of GPx1 gene might be a genetic risk factor for KBD in the Chinese population. These 
results also indicated that this polymorphism at the GPx1 locus was a common 
event in KBD development and that expression of GPx1 mRNA in KBD patients 
decreased significantly compared with controls might be involved in the pathogen-
esis of KBD. *This research is supported by National Natural Science Foundation of 
China (No. 30671820, 81172610).
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objeCtives: Kashin-Beck disease (KBD) is a chronic osteoarthropathy, prevailing in 
selenium (Se)-deficiency regions, while its etiopathogenesis maintains obscure. The 
disease mainly affects children, Se supplementation was effective in preventing KBD. 
However, Se supplementation could not entirely prevent KBD. Therefore, we investi-
gated possible association between Se and susceptibility to KBD in Xunyi county of 
Shaanxi province. Methods: 140 children who were 7-12 years old from 14 towns of 
Xunyi county were enrolled by radiography examination (X-ray of the right hand) and 
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or 25% cost reduction versus innovator etanercept pricing, resulted in projected net 
budget-savings of (millions): (1) UK € 62–162, (2) France € 19–46, (3) Germany € 42–105, 
(4) Italy € 26–62 and (5) Spain € 16–37. Such savings, could potentially fund treatment 
for an additional 1,530 (UK) to 8,430 (Germany) patients with etanercept biosimilar 
over five-years. ConClusions: The introduction of an etanercept biosimilar could 
represent substantial cost-saving potential for healthcare systems in the EU5; budget-
impact was sensitive to market uptake-rates and discounts versus etanercept. These 
savings could be used to treat additional RA patients with a biosimilar.
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objeCtives: To estimate, from a Greek payer perspective, the budget impact of 
adopting certolizumab pegol (CZP) for the treatment of axial spondyloarthritis 
(axSpA), including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-
axSpA). Methods: A budget impact model was locally adapted over a time horizon 
of 5 years, to estimate the impact of CZP taking shares from adalimumab (ADA), 
infliximab (IFX), etanercept (ETA), and golimumab (GOL), but not from conventional 
care (CC) in AS; and ADA but not CC in nr-axSpA. Data from AS and nr-axSpA popula-
tions in Greece were combined with data on market shares of available anti-TNFs 
and associated costs (i.e. medication acquisition and administration, healthcare vis-
its, laboratory and imaging tests) to estimate the budgetary consequences of CZP 
penetration. Data on the number of axSpA patients were derived from the National 
Statistical Service, published literature and expert opinion. It was assumed that the 
share of CZP will increase steadily from 5% in the first year to 13% in the fifth year 
of analysis in both populations, taking equal shares from the other biologicals. Drug 
and medical care reimbursement prices are net and reflect 2015 prices. Results: 
On average, the use of CZP is estimated to decrease the mean annual budget per AS 
patient by between € 95 to € 176 (0.9%–1.7%). On the other hand, CZP is anticipated to 
increase the annual budget per nr-axSpA patient by between € 809 to € 827 (8.6% to 
8.8%), as it costs slightly more than ADA. For the overall axSpA population, the average 
annual increase per patient ranges from € 342 to € 372 (3.4% to 3.7%), which is below 
a reimbursement threshold set by the main health insurance fund. ConClusions: 
The reimbursement of CZP for the treatment of axSpA patients in Greece will, on 
aggregate, result in a modest and acceptable increase in the total therapy cost.
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objeCtives: Biologics such as etanercept, can be efficacious in reducing disease 
activity in their authorised indications, but are considered costly. The objective of 
this study was to assess future budget-impact of introducing an etanercept biosimi-
lar in the EU5 for all licensed adult indications. Methods: A budget-impact model 
(BIM) was developed to estimate the impact of potentially introducing an etanercept 
biosimilar on the healthcare budgets in over a five-year horizon (2016-2020) from 
the payer’s perspective. Prevalence-based, incidence-based and country-specific 
model adaptations evaluate the impact of introducing an etanercept biosimilar to 
a segment of the anti-TNFs market that includes innovator etanercept and adali-
mumab for rheumatoid arthritis (RA), psoriatic arthritis (PsA) psoriasis (PsO) and 
ankylosing spondylitis (AS); comparing total costs for scenarios with and without 
the biosimilar. Patients naïve to biologics, stable on, or failing the first biologic were 
tracked under a set of conservative assumptions: (1) uptake of 5% to 40% from 
etanercept to the biosimilar; (2) anti-TNF price erosion of 5% per year; (3) unknown 
price of etanercept biosimilar – two discount scenarios versus etanercept (10%, 25%) 
were applied. Results: The hypothetical introduction of an etanercept biosimilar 
in the biologic treatment setting for scenarios with a 10% or 25% cost reduction 
compared with innovator etanercept results in projected net budget-savings of 
(millions): (1) UK € 111–284, (2) France € 35–81, (3) Germany € 76–187, (4) Italy € 46–111 
and (5) Spain € 28–65. Such savings, could be used to fund treatment for an addi-
tional 3,100 (UK) to 17,130 (Germany) patients with etanercept biosimilar over five-
years. ConClusions: The introduction of an etanercept biosimilar could represent 
substantial cost-saving potential for EU5 healthcare systems; budget-impact was 
sensitive to market uptake-rates and discounts versus etanercept. These savings 
could be used to treat additional patients with a biosimilar.
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objeCtives: To evaluate and compare the budget impact of tocilizumab intravenous 
(IV) and adalimumab subcutaneous as a 1L monotherapy for the 6-month treatment 
of patients with RA, in the Greek healthcare system Methods: A budget impact 
model was developed to evaluate the cost per response rate of the two therapeutic 
options. Clinical data were derived from a head-to-head trial (ADACTA) and referred 
to the efficacy endpoints ACR 70, DAS 28≤ 3.2 and DAS 28< 2.6. Cost and resource 
utilization data were obtained from official government sources (2014) and included 
the cost of drugs, consumables, human resources, hospital charges and patient’s 
time (productivity loss). Cost per response for both therapeutic options was esti-
mated for all three clinical endpoints from the hospital, health system and societal 
1National School of Public Health, Athens, Greece, 2University of Athens Medical School, 
Hippokration General Hospital, Athens, Greece, 3Collaborative Center for Clinical Epidemiology 
and Outcomes Research (CLEO), Athens, Greece, 4UCB Pharma, Athens, Greece
objeCtives: To estimate the incremental total and per-patient budget impact of 
adopting certolizumab pegol (CZP) for the recently indicated treatment of active 
psoriatic arthritis (PsA) in Greece. Methods: A budget impact model was adapted 
from a third-party payer perspective (EOPYY) to delineate the financial implica-
tions of introducing CZP for the treatment of PsA alongside currently indicated 
biologic treatments, namely etanercept, infliximab, adalimumab, golimumab, and 
ustekinumab, over the next 5 years (2014–2018). The model framework considered 
market share scenarios with and without CZP, and directly reimbursed costs of 
treatment and disease management, applied to the prevalent and eligible Greek 
patient population. Quarterly treatment discontinuation was geared to enable 
tracking of patients, so that the model could apply different costs to patients at 
different stages of treatment. Costs pertaining to drug acquisition, administration 
and monitoring were included for both the induction and maintenance years of 
patients’ treatment and corresponded to current costing year. Resource unit costs 
and epidemiological data were retrieved from officially published sources. The 
measured outcomes were incremental costs per treated patient per year (PTPPY) 
and total budget impact, calculated by comparing the respective patient and 
total budget expenditures with and without CZP in the market share mix scenar-
ios. Results: The incremental total and PTPPY costs resulting from the addition 
of CZP to the original treatment mix were estimated at -€ 2,036,848 (-1.76%) and 
-€ 859 respectively, over a 5-year time horizon. On average, annual cost-savings 
of € 407,370 (-1.76%) and € 172 were observed for both outcomes respectively. In 
each model, yearly cost-savings were yielded and 2018 was the year with the 
highest total cost-savings for EOPYY (€ 512,296 [-2.2%]). Cost-savings were driven 
by reduced drug and administration costs. ConClusions: The inclusion of CZP 
for active PsA treatment was predicted to be associated with short- and long-term 
cost-savings in Greece.
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objeCtives: To analyze the budgetary impact of different scenario of ten-
ders between the branded infliximab (BRANDED-INFLIX) and its biosimilars 
(BIOSIM-INFLIX) that could be implemented in the 37 public hospitals of Paris 
(AP-HP). Methods: Data collected: i) branded infliximab expenditures over the 
2012-2014 period; ii) 2014 medical information from PMSI hospital database (French 
medical information system program) to determine for which therapeutic indica-
tions the patients were treated with infliximab (gastroenterology, rheumatology, 
dermatology or others) by distinguishing infliximab-naïve patients (INFLIX-NAÏVE) 
and infliximab-experienced patients (INFLIX-EXPERIENCED). Three scenarios have 
been considered for the budget impact analysis: tender between BRANDED-INFLIX 
and BIOSIM-INFLIX to list only one infliximab in the hospital drug formulary with a 
hypothetical price decline of 20% (S1) or 30% (S2); tender between BRANDED-INFLIX 
and BIOSIM-INFLIX only for INFLIX-NAÏVE and no tender for INFLIX-EXPERIENCED 
who remain treated by BRANDED-INFLIX with a price decline of 20% and a propor-
tion of INFLIX-NAÏVE treated by BIOSIM-INFLIX of 10% (S3). Results: The branded 
infliximab represented € 42.1 million expenditures in 2014 compared to € 38.1 and 
€ 33.6 million in 2013 and in 2012 respectively. In 2014, 5483 patients were treated 
with the branded infliximab for several therapeutic indications: gastroenterology 
(61.9%), rheumatology (26.4%), dermatology (1.4%) and others (10.3%). The propor-
tions of INFLIX-NAÏVE by indication were: 35.9% in rheumatology, 32.5% in gastro-
enterology, 40.3% in dermatology and 42.8% in other indications. Over 3 years, S1 
would generate savings of € 22.8 million and S2 would save € 34.2 million, whereas 
with S3 the savings would amount to € 7.3 million (€ 4.5 million in gastroenterol-
ogy, € 2.1 million in rheumatology, € 0.1 in dermatology and € 0.6 in other indica-
tions). ConClusions: If the Committee on Medicinal Products (COMED) of AP-HP 
decides to implement tenders between BRANDED-INFLIX and BIOSIM-INFLIX the 
savings will be largely dependent on the scope of these tenders. These results could 
be considered by the COMED in its decision-making process.
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objeCtives: Rheumatoid arthritis (RA) has considerable impact on physical function 
and reduces quality of life. Biologics, such as etanercept, can be efficacious in reducing 
disease activity in their authorised indications. However, these treatment options can 
be very costly and present economic pressures on healthcare funding. The objective 
of this study was to assess budget-impact of introducing an etanercept biosimilar in 
the five largest European countries (EU5). Methods: A budget-impact model (BIM) 
was developed to estimate the impact of the hypothetical introduction of an etaner-
cept biosimilar on the healthcare budgets in EU5 over a five-year horizon (2016-2020) 
from the payer’s perspective. Prevalence-based, incidencebased and country-specific 
model adaptations evaluate the impact of introducing an etanercept biosimilar to a 
segment of the anti-TNF market that includes innovator etanercept and adalimumab; 
comparing total costs for scenarios with and without a biosimilar. Patients naïve to 
biologics, on stable treatment and failing the first biologic were tracked in the model 
under a set of conservative assumptions: (1) uptake of 5% to 40% (2016-2020) from 
etanercept to the biosimilar; (2) anti-TNF price-erosion of 5% per year; (3) unknown 
price of etanercept biosimilar – discount scenarios versus etanercept (10%, 25%) were 
applied. Results: The theoretical introduction of an etanercept biosimilar with a 10% 
